Welcome to our dedicated page for ICON PLC SEC filings (Ticker: ICLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ICON plc filings document current-report disclosures for a foreign private issuer in the clinical research organization sector. Form 6-K reports furnish press releases and exhibits on operating results, financial guidance, earnings-call scheduling, conference presentations, shareholder voting matters, governance updates, and clinical or regulatory disclosures.
The filings also record accounting-practices and internal-control matters, including revenue-recognition disclosures, as well as XBRL financial information covering operating results, equity accounts and reporting-segment data. These documents frame ICON’s public-company reporting around clinical development services, capital structure, governance and risk-related material events.
Icon plc (ICLR) reported a planned sale of 2,267 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $372,450.64, to be executed on August 11, 2026 on NASDAQ. The shares relate to restricted stock that vested under a registered plan on August 10, 2026, including 1,782 shares and 485 shares granted for services rendered.
ICON plc is registering a proposed sale of 2,677 shares of common stock under a broker arrangement with Morgan Stanley Smith Barney LLC Executive Financial Services. The shares, acquired from the issuer on 08/10/2026 through restricted stock vesting for services rendered, have an aggregate market value of $439,810.49 and are planned for sale on 08/11/2026 on the NASDAQ.
ICON PLC director Jeffrey Thomas Elliott reported a grant of 1,324 Restricted Share Units, each representing one ordinary share upon vesting. The units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. A nominal conversion price equal to the ordinary share par value of EUR 0.06 per underlying share will be automatically deducted from his pay at vesting. Following this award, he holds 1,324 Restricted Share Units directly.
ICON PLC Chief Executive Officer Barry Edward Balfe reported multiple equity transactions. On 2026-08-10 he received a grant of 22,258 Restricted Share Units, each convertible into one ordinary share, scheduled to vest in three approximately equal installments on March 8 of 2027, 2028, and 2029. He also received 32,635 stock options for ordinary shares at an exercise price of $166.05 per share, vesting in four approximately equal installments on March 8 of 2027, 2028, 2029, and 2030, and expiring on 2034-08-10, subject to limited automatic extension. On 2026-08-07, 728 Restricted Share Units from an August 7, 2023 grant vested and were converted into 728 ordinary shares. On 2026-08-10 he sold a total of 382 ordinary shares at prices of $163.80 and $165.14 per share to cover tax withholding obligations in connection with RSU vesting, which the company notes did not represent a discretionary transaction.
An affiliate of the issuer filed a Form 144 indicating an intention to sell 382 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The proposed sale is associated with restricted stock vesting under a registered plan on 08/07/2026 and is valued at approximately $62,676.12.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 5,271,320.61 shares of ICON PLC common stock, representing 6.9% of the class. FMR LLC reports sole dispositive power over all of these shares and sole voting power over 5,238,478 shares.
Abigail P. Johnson is also reported as a beneficial owner of the same 5,271,320.61 shares, with sole dispositive power and no voting power, reflecting her position related to FMR LLC and its subsidiaries. The filing notes that one or more other persons have rights to dividends or sale proceeds, but no other person holds more than 5% of ICON PLC’s common stock through these interests.
ICON plc, a global clinical research organization, has arranged the private pricing of $2.15 billion in senior unsecured notes through its wholly owned subsidiary, ICON Investments Six DAC. The notes comprise $500 million of 5.064% notes due 2029, $1.0 billion of 5.421% notes due 2031 and $650 million of 5.995% notes due 2036, all guaranteed on a senior unsecured basis by ICON. The offering is expected to close on August 13, 2026, subject to customary conditions, and is being sold in a private transaction to qualified institutional buyers.
ICON intends to use the net proceeds to repay all borrowings under its Bridge Secured Credit Facility, repay all outstanding senior secured term loans and redeem in full its 5.809% Senior Secured Notes due 2027. Upon these repayments, the collateral securing ICON’s revolving credit facility and existing notes, as well as related subsidiary guarantees, will be automatically released. ICON cautions that there can be no assurance the offering will be completed or that these debt repayments and collateral releases will occur.
ICON plc reported that all resolutions at its 31 July 2026 Annual General Meeting were duly passed on a vote base of 68,388,626 shares. Shareholders re-elected existing directors and elected new directors including Barry Balfe, Kevin Egan and Jeff Elliott, each receiving strong support such as 68,109,408 votes in favour for Mr. Balfe.
Shareholders also approved the review of the company’s affairs, auditor remuneration, authority to allot shares, and special resolutions disapplying statutory pre-emption rights (including for capital investment or acquisitions) and setting the price range for reissuing treasury shares. Authority for overseas market purchases of shares was renewed. ICON describes itself as a world‑leading clinical research organization with approximately 40,200 employees in 99 locations across 55 countries as of 30 June 2026.
ICON plc reported second quarter 2026 revenue of $2,063.5 million, up 1.4% on quarter one 2026 and 1.2% year on year. Adjusted EBITDA was $327.2 million, or 15.9% of revenue, a decrease of 21.7% versus quarter two 2025.
GAAP net income was $72.6 million, or $0.94 diluted EPS, compared with $2.56 a year earlier. Adjusted net income was $198.4 million, or $2.56 adjusted diluted EPS, down from $3.52. Results reflect items including a $32.9 million pre-tax loss on the disposal of Symphony Health Solutions Corporation and ongoing restructuring and transaction-related costs.
Demand indicators remain strong, with gross bookings of $3,681 million (up 24.1% year on year), net business wins of $3,120 million, a book-to-bill of 1.51, and backlog of $23.4 billion, up 3.0% on quarter one 2026. Free cash flow was $238.9 million, cash and cash equivalents were $928.4 million, and net debt was $2.5 billion, a net debt to adjusted EBITDA ratio of 1.8x. Year to date, revenue reached $4,097.5 million and adjusted diluted EPS was $5.06. ICON reaffirmed 2026 guidance for revenue of $7,850–$8,150 million and adjusted diluted EPS of $10.00–$11.00.